Indie brand launched a brightening line on Melitane and Melanostatine-5 with claim-safe framing
An indie brand building its first brightening line wanted the two melanocortin-pathway peptides — Melitane and Melanostatine-5 — front and centre, with claim language that stayed cosmetic. Per-active documentation and claim-framing notes took the line from brief to first fill in 11 weeks.
Published May 22, 2026 · Anonymized customer story
Brief → first commercial fill
~11 weeks
Retailer claims review
1 (first-submission clearance)
Actives qualified
2 · Melitane + Melanostatine-5
Carrier-validation passes
1 (shared base)
Challenge
The brand wanted to enter the brightening category with a two-product line — a day even-tone serum and a night radiance treatment — built around Acetyl Hexapeptide-1 (Melitane) and Nonapeptide-1 (Melanostatine-5). The founder had read enough to know the two peptides 'both work on the melanin receptor' but not that they are studied at opposite ends of MC1-R, and the first-draft marketing copy leaned on lightening language that would not survive a US retailer's claims review. The Head of Brand needed a supplier that could ship both actives at cosmetic grade with INCI documentation, explain the agonist-versus-antagonist distinction in plain terms, and provide claim-framing notes that kept the line at the appearance level — all inside an 11-week launch window for a seasonal radiance push.
Approach
Pepoderma's brand partnerships team supplied both actives from the new Brightening & Radiance range with INCI name, CAS, and an allergen and trace-impurity sheet per lot, plus a plain-language briefing on the mechanistic distinction: Melanostatine-5 studied as a proposed α-MSH antagonist (the even-tone signal-blocker), Melitane studied as a proposed α-MSH agonist (MC1-R-pathway modulation and photoprotective support). The accompanying claim-framing card rewrote the draft copy around the appearance of even tone and radiance, removed the lightening and anti-hyperpigmentation language, and steered Melitane away from being called a 'brightener' in the lightening sense given its studied agonist role. Both actives are water-soluble, so the carrier guidance was a single shared near-neutral aqueous base with the actives added cool and late; 100 g samples of each went to the contract manufacturer for a combined validation pass.
Outcome
The contract manufacturer validated both peptides in the shared base in one pass, and first commercial fill of the two-product line shipped close to the 11-week target, on the seasonal calendar. The retailer's claims review cleared the reframed copy on first submission — the appearance-level language and the per-active INCI documentation gave the reviewer what they needed — and the brand was able to tell a two-active 'multi-vector even-tone' story on pack without crossing into medical or efficacy territory. The founder cited the agonist/antagonist briefing as the moment the line's positioning actually made sense.
“We genuinely thought the two peptides did the same thing. Having it explained that one is studied as blocking the signal and one as an agonist — and getting copy that kept us on the right side of the claims line — is what let our retailer wave the line through on the first pass.”